Publication: FATZO Mouse - Improved Model for Preclinical Screening of Agents to Stop or Slow Progression to Severe Diabetes

Peterson RG, Jackson CV, Zimmerman KM, Alsina-Fernandez J, Michael MD, Emmerson PJ, et al. (2017) Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse. PLOS ONE 12(6): e0179856.

CrownBio 2017. Publication. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouseThe FATZO/Pco mouse is an inbred strain exhibiting obesity in the presumed presence of an intact leptin pathway. Routinely used rodent models for obesity and diabetes research have a monogenic defect in leptin signaling that initiates obesity. Given that obesity in humans is not associated with leptin signaling defects, the FATZO mouse represents a more translatable rodent model for study of obesity and diabetes.

This publication aimed to assessed the utility of this new model for the preclinical screening of agents to stop or slow progression of the metabolic syndrome to severe diabetes.

Download This Publication To Understand:

  • The spontaneous development of disease in FATZO mice
  • The comparison of metabolic disturbances of FATZO mice to control mice
  • How the model was validated by assessing the effectiveness of current and emerging anti-diabetic agents; rosiglitazone, metformin and semaglutide

Download The Publication Now!

Get Your Copy!

Your privacy is important to us.
We'll never share your information.

SHARE THIS